LY 2599666

Drug Profile

LY 2599666

Alternative Names: LY2599666

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Nootropics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Dec 2016 Eli Lilly terminates a phase I trial in Alzheimer's disease in USA and Japan (SC) (NCT02614131)
  • 01 Dec 2015 Phase-I clinical trials in Alzheimer's disease in Japan, USA (SC)
  • 30 Nov 2015 Preclinical trials in Alzheimer's disease in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top